Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods

Yuxi Cheng; Zhengzheng Song; Juan Chen; Zhangui Tang; Baisheng Wang

doi:10.1016/j.heliyon.2024.e25895

Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1/PD-L1 related immunotherapy methods

Heliyon. 2024 Feb 10;10(4):e25895. doi: 10.1016/j.heliyon.2024.e25895. eCollection 2024 Feb 29.

Authors

Yuxi Cheng^{1

2

3}, Zhengzheng Song^{1

2

3}, Juan Chen^{1

2

3}, Zhangui Tang^{1

2

3}, Baisheng Wang^{1

2

3}

Affiliations

¹ Xiangya Stomatological Hospital, Central South University, Changsha, 410008, China.
² Xiangya School of Stomatology, Central South University, Changsha, 410008, China.
³ Clinical Research Center of Oral Major Diseases and Oral Health, 410008, Hunan, China.

Abstract

Oral squamous cell carcinoma (OSCC) affects a large number of individuals worldwide. Despite advancements in surgery, radiation, and chemotherapy, satisfactory outcomes have not been achieved. In recent years, the success of drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) has led to breakthroughs in cancer treatment, but systematic summaries on their effectiveness against OSCC are lacking. This article reviews the latest research on the PD-1/PD-L1 pathway and the potential of combination therapy based on this pathway in OSCC. Further, it explores the mechanisms involved in the interaction of this pathway with exosomes and protein-protein interactions, and concludes with potential future OSCC therapeutic strategies.

Keywords: Biomarker; EGFR blockade; ICB; Oral squamous cell carcinoma; PD-1; PD-L1.

Publication types

Review